Ipek Erdogan-Trinkaus, Chief Commercial Officer, sold 3,500 shares of Eton Pharmaceuticals, Inc. at $67.18 to $67.88 a share (average $67.41) in 2 transactions, worth $236K in total on Nov 10, 2026. Shares held after the trade: 4,081 (-22.1%).
Eton Pharmaceuticals Insider Charles J. Casamento Sells $5.35M of Stock
Charles J. Casamento sold 80,555 shares of Eton Pharmaceuticals, Inc. at $64.33 to $67.87 a share (average $66.35) in 5 transactions, worth $5.35M in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
Eton Pharmaceuticals delivered a massive Q3 2026 beat, driven by Hemangiol's full-quarter contribution and record patient counts across all branded products, significantly accelerating their long-term revenue and margin targets.
Eton Pharmaceuticals reported a significant increase in net revenues to $57.9 million for the third quarter of 2026, driven by strong product sales. The company achieved a net income of $35.2 million for the quarter, aided by a $12.9 million income tax benefit related to the reversal of a deferred tax asset valuation allowance.
Eton Pharmaceuticals reported record Q3 2026 revenue of $57.9 million, representing 158% year-over-year growth and surpassing its $200 million annualized revenue run rate goal ahead of schedule. The company achieved a 49% Adjusted EBITDA margin and raised its full-year 2026 revenue guidance to over $175 million.
Term
Q3 2026
“Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%.”
Sean Brynjelsen, CEO of Eton Pharmaceuticals
“We have also made transformational improvements to our pipeline in recent months with ASN-001 for infantile hemangiomas, and ET-900, our new program evaluating mecasermin in infantile and epileptic spasms.”
Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.
“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”
Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine
Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.
Eton Pharmaceuticals Signs $10M M&A Deal with Aquestive Therapeutics, Inc.
Eton Pharmaceuticals acquired exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film from Aquestive Therapeutics for an upfront fee of $10 million and up to $47.5 million in milestones. The deal includes a 20-year supply agreement and targets the $450 million annual U.S. seizure rescue market with an anticipated launch in April 2027.
Eton Pharmaceuticals Chief Business Officer David Krempa Sells $229K of Stock
David Krempa, Chief Business Officer, sold 4,166 shares of Eton Pharmaceuticals, Inc. at $55.07 a share, worth $229K in total on Oct 6, 2026. Shares held after the trade: 43,381 (-8.8%).
Eton Pharmaceuticals has launched IMPAVIDO (miltefosine) capsules in the United States for the treatment of visceral, cutaneous, and mucosal leishmaniasis. The company has integrated the product into its Eton Cares rare disease commercial infrastructure, providing patient support services and centralized distribution through Anovo Specialty Pharmacy.